Exploring new ways to block protein interactions in cancer treatment
Official title: Covalent PD1 Antagonists: Discovery of Protein-Protein Interaction (PPI) Inhibitors in Cancer Immunotherapy
Funded at Florida Atlantic University · NIH-10994616 · Data updated 2026-11-12
This study is exploring new ways to block certain protein interactions that help cancer grow, using special tools and techniques, with the hope of creating better treatments that could help patients respond more effectively to cancer therapy.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida Atlantic University NIH-funded |
| Lab location | 1 site (Boca Raton, United States) |
| Project start | December 5, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $71,467 |
| NIH project number | 5R03CA286528-02 |
| Project ID | NIH-10994616 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancer who may benefit from new immunotherapy treatments.
✕Less likely to help
Patients with non-cancerous conditions or those who do not respond to immunotherapy may not receive benefits from this research.
What this research studies
This research investigates innovative methods to inhibit protein-protein interactions (PPIs) that are crucial in cancer biology. By utilizing advanced proteomic tools and gene-editing techniques, the project aims to develop novel PPI inhibitors using β-hairpin peptides that mimic antibody structures. This approach seeks to enhance the specificity and effectiveness of cancer immunotherapy by targeting specific interactions that contribute to tumor growth and immune evasion. Patients may benefit from new therapeutic options that could improve their response to cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance the body's ability to fight tumors.
How similar studies have gone: Other research has shown promise in targeting protein-protein interactions for cancer treatment, indicating that this approach could be a viable strategy.
Where this research is happening
-
Florida Atlantic University
Boca Raton, United States Active
Researchers
- Principal investigator: Roche, Stephane P — Florida Atlantic University
- Study coordinator: Roche, Stephane P
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.